Palatin Technologies (PTN) AI Stock Analysis

• Market Cap: $6.13M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 0.23
• Revenue Growth: -95.07%
• EPS Growth: 40.41%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 28,148,846
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.10
• Enterprise Value/Market Cap: -0.07
• Enterprise Value/Revenue: -0.03
• Enterprise Value/Gross Profit: -2.30
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $7.00
• Price Target Upside: 6900.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 37 Underperform
• Price Target: ―

Palatin Technologies is facing significant financial and operational challenges, with persistent losses, negative equity, and weak cash flow. The technical analysis indicates a bearish outlook, and valuation metrics reflect the company’s struggles. Despite some positive elements from the earnings call, such as reduced net loss and potential partnerships, the lack of product sales and decreasing cash reserves are concerning. Immediate improvements are needed to enhance financial stability and shareholder value.

Positive Factors

Clinical Trials

The completion of the Phase 2 BMT-801 clinical trial is a significant milestone for Palatin as it focuses on the obesity space, which is seen as a key driver of the company's long-term success.

Strategic Focus

Palatin's strategic focus has shifted primarily to its obesity program, which management views as the primary driver of long-term success.

Negative Factors

Clinical Trial Risks

Factors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.

Financial Needs

The company is in talks with sources to address its future operating cash needs.

Palatin Technologies Business Overview & Revenue Model

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

How the Company Makes Money

Palatin Technologies generates revenue through the commercialization of its FDA-approved product, Vyleesi, which is licensed to AMAG Pharmaceuticals in North America. The company earns income from product sales, royalties, and milestone payments associated with this partnership. Additionally, Palatin seeks to expand its revenue streams by developing and potentially licensing other therapeutic peptide products in its pipeline. The company's financial health is also supported by strategic collaborations and partnerships with other pharmaceutical companies, providing additional funding and resources for its research and development efforts.

Palatin Technologies Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	350.00K	4.49M	4.85M	1.47M	-188.60K	117.99K
Gross Profit	178.21K	4.39M	4.44M	1.25M	-336.44K	-13.84M
EBITDA	-26.53M	-29.03M	-32.46M	-35.68M	-33.38M	-22.04M
Net Income	-26.95M	-29.74M	-27.54M	-35.81M	-33.57M	-22.38M
Balance Sheet
Total Assets	4.31M	10.74M	17.94M	36.07M	67.30M	85.05M
Cash, Cash Equivalents and Short-Term Investments	3.42M	9.53M	10.98M	29.94M	60.10M	82.85M
Total Debt	357.74K	590.34K	1.05M	1.15M	1.25M	1.27M
Total Liabilities	10.69M	10.85M	17.81M	19.80M	17.65M	4.88M
Stockholders Equity	-6.38M	-111.50K	134.07K	16.27M	49.65M	80.17M
Cash Flow
Free Cash Flow	-26.95M	-31.50M	-28.85M	-30.18M	-22.65M	41.26M
Operating Cash Flow	-26.94M	-31.46M	-28.42M	-29.92M	-22.65M	41.33M
Investing Cash Flow	2.50M	12.45M	-3.43M	-261.37K	-5.72K	-62.88K
Financing Cash Flow	18.38M	20.55M	9.90M	18.36K	-93.64K	-1.92M

Palatin Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
LPCN	48 Neutral	$16.96M	650.59	-24.89%	―	10081.34%	―
BOLT	45 Neutral	$11.00M	―	-83.92%	―	-67.87%	0.40%
CLDI	37 Underperform	$21.82M	―	354.78%	―	―	64.19%
PTN	37 Underperform	$6.13M	―	422.38%	―	-95.07%	40.41%
EDSA	35 Underperform	$15.31M	―	-58.78%	―	―	-126.54%
GOVX	34 Underperform	$18.48M	―	-616.17%	―	―	71.39%